We are live on ! Find out more
UOC

UBS O'Connor Portfolio holdings

AUM $3.38B
1-Year Est. Return 63.08%
This Fund
S&P 500
This Quarter Est. Return
+10.93%
1 Year Est. Return
+63.08%
3 Year Est. Return
+180.99%
5 Year Est. Return
+483.22%
10 Year Est. Return
+2,128.62%
AUM
$3.18B
AUM Growth
-$2.44B
Cap. Flow
-$2.64B
Cap. Flow %
-83.08%
Top 10 Hldgs %
60.78%
Holding
672
New
112
Increased
61
Reduced
251
Closed
169

Sector Composition

Rank Sector Weight
1 Energy 29.51%
2 Technology 21.97%
3 Healthcare 10.49%
4 Real Estate 7.26%
5 Industrials 4.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
XAGEW
401
DELISTED
Longevity Health Holdings, Inc. Warrant
XAGEW
$82.8K ﹤0.01%
371,250
MGM icon
402
PUT
MGM Resorts International
MGM
$11.3B
$82.1K ﹤0.01%
35,000
TV icon
403
CALL
Televisa
TV
$1.5B
$80.8K ﹤0.01%
+73,500
New +$208K
BPMC
404
CALL
DELISTED
Blueprint Medicines
BPMC
$72K ﹤0.01%
10,000
-15,000
-60% -$972K
INSM icon
405
CALL
Insmed
INSM
$28.2B
$71.3K ﹤0.01%
+30,000
New +$778K
SPY icon
406
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$822B
$68K ﹤0.01%
277,500
+167,500
+152% +$74.6M
CRNX icon
407
CALL
Crinetics Pharmaceuticals
CRNX
$8.9B
$67.5K ﹤0.01%
30,000
-30,000
-50% -$920K
ROIV icon
408
CALL
Roivant Sciences
ROIV
$26B
$62.5K ﹤0.01%
+100,000
New +$975K
TGTX icon
409
CALL
TG Therapeutics
TGTX
$7.6B
$55K ﹤0.01%
+50,000
New +$581K
THRX
410
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$50.7K ﹤0.01%
12,517
-168,935
-93% -$515K
NCLH icon
411
PUT
Norwegian Cruise Line
NCLH
$8.81B
$48.2K ﹤0.01%
55,100
CZR icon
412
PUT
Caesars Entertainment
CZR
$6.14B
$44.2K ﹤0.01%
15,000
BIIB icon
413
CALL
Biogen
BIIB
$30.5B
$44K ﹤0.01%
+10,000
New +$2.46M
ARDX icon
414
CALL
Ardelyx
ARDX
$988M
$37.5K ﹤0.01%
150,000
WDC icon
415
PUT
Western Digital
WDC
$149B
$35.5K ﹤0.01%
19,184
BMRN icon
416
CALL
BioMarin Pharmaceuticals
BMRN
$12.2B
$31.2K ﹤0.01%
+43,000
New +$3.8M
UAL icon
417
PUT
United Airlines
UAL
$42.1B
$30.5K ﹤0.01%
333,900
RDN icon
418
PUT
Radian Group
RDN
$4.93B
$27.5K ﹤0.01%
50,000
-4,900
-9% -$129K
GAQ.WS
419
DELISTED
Generation Asia I Acquisition Limited Redeemable Warrants included as part of the units, each whole warrant exercisable for one Class A ordinary share at an exercise price of $11.50
GAQ.WS
$26.4K ﹤0.01%
938,800
XLF icon
420
PUT
State Street Financial Select Sector SPDR ETF
XLF
$58.3B
$24.8K ﹤0.01%
+450,000
New +$15.6M
CVIIW
421
DELISTED
Churchill Capital Corp VII Warrants
CVIIW
$23.9K ﹤0.01%
133,530
-60,018
-31% -$9.97K
SKGRW
422
DELISTED
SK Growth Opportunities Corporation Warrant
SKGRW
$23.4K ﹤0.01%
+420,833
New +$23K
UBER icon
423
PUT
Uber
UBER
$153B
$23.2K ﹤0.01%
+170,000
New +$8.89M
RCUS icon
424
CALL
Arcus Biosciences
RCUS
$3.6B
$22.8K ﹤0.01%
35,000
QURE icon
425
CALL
uniQure
QURE
$3.18B
$22.5K ﹤0.01%
90,600
+600
+0.7% +$3.96K

Similar funds

UBS O'Connor's Q4 2023 Portfolio in Review

As of Q4 2023, UBS O'Connor held 672 positions worth $3.18B, down 43% from $5.62B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

UBS O'Connor withdrew a net $2.64B in Q4 2023, closing 169 positions and reducing 251 holdings. Its most notable exit was Activision Blizzard, an estimated $1.06B position sold in full.

By sector, the portfolio is most concentrated in Energy at 30% of assets, up from 3.6% a quarter earlier, followed by Technology and Healthcare.

Against the trend, UBS O'Connor opened a new position in Pioneer Natural Resource Co. worth $579M.

  • UBS O'Connor's largest Q4 2023 buy was Pioneer Natural Resource Co.: 2,576,808 shares worth $579M.
  • UBS O'Connor added most to Splunk Inc in Q4 2023, an estimated $446M increase.
  • UBS O'Connor's biggest Q4 2023 reduction was Capri Holdings, cutting an estimated $36.6M.
  • UBS O'Connor fully exited Activision Blizzard in Q4 2023, selling an estimated $1.06B.
  • UBS O'Connor's ten largest holdings make up 61% of its $3.18B portfolio in Q4 2023.
  • UBS O'Connor opened 112 new positions and closed 169 in Q4 2023.
  • UBS O'Connor's portfolio value fell 43% quarter-over-quarter to $3.18B.

Based on UBS O'Connor's 13F filing for Q4 2023, filed 14 Feb 2024.